Search results
Results from the WOW.Com Content Network
Systemic scleroderma is a rare disease, with an annual incidence that varies in different populations. Estimates of incidence (new cases per million people) range from 3.7 to 43 in the United Kingdom and Europe, 7.2 in Japan, 10.9 in Taiwan, 12.0 to 22.8 in Australia, 13.9 to 21.0 in the United States, and 21.2 in Buenos Aires. [ 48 ]
Channel 5 (also known as "Channel 5 with Andrew Callaghan" on YouTube) is an American digital media company and web channel, billed as a "digital journalism experience." [ 2 ] The show is a spinoff of the group's previous project, All Gas No Brakes , which was itself based on the book of the same name.
As of 2012, the five-year survival rate for systemic scleroderma was about 85%, whereas the 10-year survival rate was just under 70%. [44] This varies according to the subtype; while localized scleroderma rarely results in death, the systemic form can, and the diffuse systemic form carries a worse prognosis than the limited form.
The idea behind the "mixed" disease is that this specific autoantibody is also present in other autoimmune diseases such as systemic lupus erythematosus, polymyositis, scleroderma, etc. MCTD was characterized as an individual disease in 1972 by Sharp et al., [3] [4] and the term was introduced by Leroy [5] in 1980. [6]
Scleromyositis, is an autoimmune disease (a disease in which the immune system attacks the body). People with scleromyositis have symptoms of both systemic scleroderma and either polymyositis or dermatomyositis, and is therefore considered an overlap syndrome.
CREST syndrome, also known as the limited cutaneous form of systemic sclerosis (lcSSc), is a multisystem connective tissue disorder. The acronym "CREST" refers to the five main features: calcinosis , Raynaud's phenomenon , esophageal dysmotility , sclerodactyly , and telangiectasia .
DR5 is associated with persistent generalized lymphadenopathy [3] and Kaposi's sarcoma in AIDS, [4] juvenile rheumatoid arthritis, [5] [6] pernicious anemia, Hashimoto's thyroiditis, [7] [8] mycosis fungoides, [9] polyglandular deficiency syndrome, [10] systemic sclerosis, [11] [12] childhood epilepsy, [13] early-onset alopecia areata, [14] short-ragweed Ra6 allergy, [15] primary ...
Anti-Scl-70 (also called anti-topoisomerase I after the type I topoisomerase target [1]) is an anti-topoisomerase antibody-type of anti-nuclear autoantibodies, seen mainly in diffuse systemic scleroderma (with a sensitivity of 28–70%), but is also seen in 10–18% of cases of the more limited form of systemic scleroderma called CREST syndrome. [2]